Cerecor (NASDAQ:CERC) Downgraded by ValuEngine
Several other analysts have also recently issued reports on the company. HC Wainwright set a $28.00 price objective on Denali Therapeutics and gave the stock a “buy” rating in a report on Monday. Maxim Group assumed coverage on Entera Bio in a report on Tuesday, July 2nd. They set a “buy” rating and a $12.00 price objective on the stock. TheStreet cut Virtusa from a “b-” rating to a “c+” rating in a report on Wednesday, May 29th. Finally, LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $8.00 price objective on shares of Cerecor in a report on Tuesday, July 2nd. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Cerecor has an average rating of “Buy” and a consensus price target of $9.67.
CERC stock traded down $0.02 during midday trading on Friday, hitting $4.60. The company’s stock had a trading volume of 49,931 shares, compared to its average volume of 139,262. Cerecor has a 12 month low of $2.71 and a 12 month high of $7.65. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.95 and a quick ratio of 0.91. The business has a 50 day moving average price of $5.10.
In related news, major shareholder Armistice Capital Master Fund purchased 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The shares were bought at an average price of $4.97 per share, for a total transaction of $99,400.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Simon Pedder purchased 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The shares were bought at an average price of $5.06 per share, for a total transaction of $30,360.00. Following the acquisition, the insider now directly owns 6,000 shares in the company, valued at approximately $30,360. The disclosure for this purchase can be found here. Insiders have bought a total of 225,219 shares of company stock worth $1,077,864 over the last ninety days. Insiders own 64.30% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new stake in Cerecor during the 1st quarter valued at $109,000. Northern Trust Corp raised its holdings in Cerecor by 47.9% during the 4th quarter. Northern Trust Corp now owns 20,079 shares of the company’s stock valued at $65,000 after buying an additional 6,500 shares during the period. BlackRock Inc. raised its holdings in Cerecor by 18.5% during the 4th quarter. BlackRock Inc. now owns 33,960 shares of the company’s stock valued at $109,000 after buying an additional 5,293 shares during the period. Tibra Equities Europe Ltd purchased a new stake in Cerecor during the 1st quarter valued at $210,000. Finally, Spark Investment Management LLC raised its holdings in Cerecor by 60.5% during the 1st quarter. Spark Investment Management LLC now owns 83,000 shares of the company’s stock valued at $484,000 after buying an additional 31,290 shares during the period. Institutional investors own 53.90% of the company’s stock.
Cerecor Company Profile
Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.
Recommended Story: What are retained earnings?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.